Aclaris Therapeutics, Inc. · NASDAQ:ACRS

Aclaris Therapeutics — Investor Presentation (September 2016)

13 slides from Aclaris Therapeutics's investor presentation, Sep 13, 2016

  1. Slide 1: Verruca Vulgaris (Common Warts) Market Opportunity

    September 2016 © Copyright 2016 Aclaris Therapeutics. All rights reserved. Verruca Vulgaris (Common Warts) Market Opportunity

  2. Slide 2: Summary of A-101 Phase 2 Wart Clinical Trial Results

    Trial Common Wart Area Topline Data Trial Objective and Design Trial Outcome WART–201 (n=98) Phase 2 Trunk and Extremities August 2016 Multicenter, parallel group One wart treated A-101 concentrations: 40%, 45% compared to vehicle 8 applications Duration: 56 days Efficacy: Statistically significant

  3. Slide 3: Both Statistical and Clinical Significance Achieved on Primary Endpoint with A-101 45%

    September 2016 3 Both Statistical and Clinical Significance Achieved on Primary Endpoint with A-101 45% Concentration MEAN CHANGE FROM BASELINE IN THE PWA SCORE AT VISIT 10 Baseline Day 7 Day 14 Day 21 Day 28 Day 35 Day 42 Day 49 Day 56 -1.2 0 -0.2 -0.4 -0.6 -0.8 -1 ** * *

  4. Slide 4: Statistical Significance Achieved on Secondary Endpoints in Clearance of Common Warts

    Statistical Significance Achieved on Secondary Endpoints in Clearance of Common Warts with A-101 45% Concentration Responder Analysis PROPORTION OF SUBJECTS ACHIEVING WART CLEARANCE AT VISIT 10 P- value = 0.02 PROPORTION OF SUBJECTS ACHIEVING CLEAR OR BARELY EVIDENT ON PWA AT VISIT 10 A-101 45.0% A-

  5. Slide 5: Patient Treated with A-101 45% Concentration in study WART-201

    Patient Treated with A-101 45% Concentration in study WART-201 Subject: 04-52 Visit: 2 Date: 07Jul2014 Lesion: 3 H2O2%: 40.0 PLA: 3 Pre-Treatment with A-101 Post-Treatment with A-101 Visit 2 (PLA 3) Visit 10 (PLA 0) September 2016 5

  6. Slide 6: Skin Reactions Similar to Vehicle at Visit 10; Favorable Safety Profile

    Skin Reactions Similar to Vehicle at Visit 10; Favorable Safety Profile No Reaction Mild Moderate Vesicles/Bullae September 2016 6 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% A-101 Solution 40% A-101 Solution 45% A-101 Solution Vehicle A-101 Solution 40% A-101 Solution 45% A-101 Solution Vehicle A-1

  7. Slide 7: A-101 45% Concentration Considered for Further Development as Treatment for Common Warts

    Based on Results, A-101 45% Concentration Considered for Further Development as Treatment for Common Warts Statistical Significance Achieved both statistical and clinical significance on the primary endpoint Achieved statistical significance in complete clearance of the warts Safety Profile Favorabl

  8. Slide 8: Verruca Vulgaris (Common Warts): Common Skin Disease

    Verruca Vulgaris (Common Warts): Common Skin Disease 1 Silverberg et al, The US Prevalence of Common Warts in Childhood: A Population-Based Study, Journal of Investigative Dermatology; 2013; 133, 2788–2790. Etiology – keratinocytes infected by human papillomavirus (HPV); manifests as common warts, p

  9. Slide 9: Patient Desire for Treatment

    50% of patients report discomfort1 39% of patients say warts impact social/leisure activities1 Perceived social stigma,2 possibly due to contagious nature Warts can persist for years In children, up to 2/3 of warts may resolve within two years3 Warts that do not clear within a year are unlikely to d

  10. Slide 10: Treatment Guidelines for Common Warts

    Treatment Guidelines for Common Warts Patient wishes to prevent spread to self or to others Patient complains of pain, bleeding, itching, burning Disabling or disfiguring lesions present Numerous or very large lesions present Patient is immunocompromised Patient desires therapy TREATMENT GUIDELINES

  11. Slide 11: Significant Unmet Need Exists

    Lack of rigorous clinical studies Slow to work Recurrence rate is high Significant Unmet Need Exists 1 IMS National Disease and Therapeutic Index 2016. 2 Lipke M., An Armamentarium of Wart Treatments, Clinical Medicine & Research,4:4, 2006; 273–293. 3 Sterling et al, British Association of Dermatolo

  12. Slide 12: Current Patient Base

    Current Patient Base 1 IMS National Disease and Therapeutic Index 2016. 2 Bruggnik et al, Natural Course of Cutaneous Warts Among Primary Schoolchildren: A Prospective Cohort Study 2013, Annals of Family Medicine;11:5,2013;437-441. 3 Lipke M., An Armamentarium of Wart Treatments, Clinical Medicine &

  13. Slide 13: Thank You

    © Copyright 2016 Aclaris Therapeutics. All rights reserved. THANK YOU www.aclaristx.com

Aclaris Therapeutics — Investor Presentation (September 2016) on 6ix